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Background: This paper presents a protocol for a randomised controlled trial of the Cardiac-Diabetes Transcare program
which is a transitional care, multi-modal self-management program for patients with acute coronary syndrome comorbid
with type 2 diabetes. Prior research has indicated people hospitalised with dual cardiac and diabetes diagnoses are at an
elevated risk of hospital readmissions, morbidity and mortality. The primary aim of this study is to evaluate the effectiveness
(and cost-effectiveness) of a Cardiac-Diabetes Transcare intervention program on 6-month readmission rate in comparison
to usual care.
Methods/Design: A two-armed, randomised controlled trial with blinded outcome assessment will be conducted to
evaluate the comparative effectiveness of two modes of care, including a Usual Care Group and a Cardiac-Diabetes
Transcare Intervention (in addition to usual care) Group. The primary outcome is 6-month readmission rate, although
a range of secondary outcomes will be collected (including self-efficacy) at baseline, 1, 3 and 6 month reassessments.
The intervention group will receive in-hospital education tailored for people recovering from an acute coronary
syndrome-related hospital admission who have comorbid diabetes, and they will also receive home visits and telephone
follow-up by a trained Research Nurse to reinforce and facilitate disease-management-related behaviour change. Both
groups will receive usual care interventions offered or referred from participating hospital facilities. A sample size of 432
participants from participating hospitals in the Australian states of Queensland and Victoria will be recruited for 90%
power based on the most conservative scenarios modelled for sample size estimates.
Discussion: The study outlined in this protocol will provide valuable insight into the effectiveness of a transitional care
intervention targeted for people admitted to hospital with cardiac-related presentations commencing in the inpatient
hospital setting and transition to the home environment. The purpose of theory-based intervention comprising face-to-face
sessions and telephone follow up for patients with acute coronary syndrome and type 2 diabetes is to increase self-efficacy
to enhance self-management behaviours and thus improve health outcomes and reduce hospital readmissions.
Trial registration: This study has been registered with the Australian New Zealand Clinical Trials Registry dated 16/12/2014:
ACTRN12614001317684.
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Fig. 1 Study design and procedure overview
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Cardiovascular disease and diabetes mellitus are contrib-
uting to a dual chronic disease epidemic. The Organisa-
tion for Economic Co-operation and Development
(OECD) reported data compiled from its member’s
countries in 2011, identifying that these diseases caused
nearly one-third of all recorded deaths [1]. Estimating
numbers of patients with both conditions is difficult as
data have been primarily collected with single-disease
specificity, despite acknowledgement of increasing
multi-morbidity [2]. In Australia, where the present
study is being conducted, it is difficult to illustrate a
complete picture of the proportion of cases of cardiovas-
cular related disease and diabetes, in particular type 2
diabetes mellitus, as there are no national registries of
these diseases [3].
Historically, the patient self-management programs
that have shown to improve clinical outcomes have fo-
cussed on a specific disease or clinical presentation.
However, patients with both cardiac conditions and
diabetes have higher rates of re-hospitalisation than
those with only one disease [4]. A previous study by in-
vestigators of this trial identified that patients with both
acute coronary syndrome (ACS) and type 2 diabetes
were three-fold more likely to be readmitted to an acute
hospital within 28 days of discharge, compared to
patients with only ACS [4]. Higher readmission rates
translate to greater impact physically, emotionally and
financially for patients and health services [5].
Inpatient hospital education programs can influence a
patient’s management of their chronic disease, yet there
is inconclusive evidence on adherence to treatment rec-
ommendations for patients with multiple conditions [6].
Qualitative evidence from patients’ perspectives has indi-
cated that disease management programs that only focus
on one of an individual’s multiple chronic conditions
can create confusion and uncertainty regarding which
condition should take priority for treatment [7].
Discharge planning models of care have been identified
for patients with singular chronic diseases, and for older
patients identified as having risk factors for readmission
[8]. A Cochrane Review published in 2013, reported that
when discharge planning is tailored to individual needs
it is more likely to lead to a reduction in readmission
[9]. The present study includes an intervention that can
be tailored to the individual needs of patients with both
cardiac disease and diabetes with the intention of
increasing patients’ self-efficacy in managing both of
these conditions.
Programs incorporating strategies promoting self-
efficacy have demonstrated potential to translate into
behaviour change [10]. The features of the cardiac-
diabetes self-management program (CDSMP) to be eval-
uated in the present study have been discussed in detailpreviously [11–15]. In summary, the CDSMP has been
developed for patients with dual cardiac and diabetes
diagnoses and strategies included in the program have
their foundation in Bandura’s theory of self-efficacy [16,
17]. Literature examining different program delivery
modalities has indicated that a combination of an in-
hospital multi-media based education, followed by an
early in-home visit and telephone call follow-up can be a
relatively inexpensive, interactive and effective approach
for reducing unplanned hospital re-admissions [18].
However, this approach has not been trialled specifically
among a population of cardiac patients with type 2
diabetes, which is the target clinical group for the
Cardiac-Diabetes Transcare intervention to be trialled in
this investigation.
Aims
The aims of the proposed study are to evaluate the effect
of the Cardiac-Diabetes Transcare Program on the pri-
mary outcome of 6-month readmission rates, as well as
secondary outcomes of health status, health-related
quality of life, and self-efficacy that will be recorded at
baseline, 1, 3, and 6 months. A further aim is to evaluate
the cost-effectiveness of this intervention from the per-
spective of the healthcare system.
Methods
Design
A two armed, randomised controlled trial with blinded
outcome assessment will be conducted with a 6 month
follow-up (Fig. 1). This trial will evaluate the compara-
tive effectiveness of Usual Care (Group 1) and the
Cardiac-Diabetes Transcare Program (Intervention)
which will provide education, in-home visits and
Wu et al. BMC Health Services Research  (2017) 17:109 Page 3 of 7telephone follow-up by a Research Nurse (ResN) in
addition to their usual care (Group 2).
Sample size considerations
A target sample of 432 patients (with an anticipated at-
trition rate of 20% over the 6 month follow-up period)
will be recruited from participating hospital facilities in
Australia. The participating hospitals include the Royal
Brisbane and Women’s Hospital (929-bed tertiary refer-
ral public hospital, located in Brisbane, Queensland,
Australia), and the St Vincent’s Hospital, Melbourne
(504-bed tertiary referral metropolitan hospital, located
in Melbourne, Australia).
Completed data on 173 patients per group will enable
over 90% power to detect 17.5% difference between
groups in 6-month readmission rate (30% versus 47.5%)
with alpha = 0.05. The assumptions for this sample size
calculation were based on a more conservative antici-
pated effect than the large effect observed in a subgroup
of patients (n = 49) with comorbid cardiac condition and
diabetes from a randomised trial previously conducted
by investigators of the present trial [8]. The previous
study similarly included an intervention comprising a
home visit and 6-month follow up, but was not tailored
for patients with dual ACS and type 2 diabetes and in-
stead targeted older adults who had been hospitalised.
The sub-group analysis indicated a large effect of the
intervention resulting in a 31.5% (intervention 25.0%
versus usual care 56.5%) between group differences in
raw 6-month readmission rates.
However, due to potential differences in sample char-
acteristics between the prior trial sub-group and the tar-
get sample of the present study that may be associated
with readmission rates, an interim analysis of hospital
re-presentation event rate will be undertaken. This ana-
lysis will examine the 3-month readmission rate in the
present study (both groups combined) to see whether it
is higher or lower than rates used in the sample size
calculation. This will be conducted using the first (ap-
proximately) 10% of the target sample to reach the
3-month re-assessment point, by a statistician not in-
volved in the day-to-day operations of the trial. The stat-
istician will be provided with a dataset from each trial
site that does not include a variable for group allocation
and no attempt to compare event rates between groups
during the interim analysis will occur. Rather the sole
purpose of the event rate interim analysis is to verify or
refute whether the difference in readmission rates used
in the initial sample estimate is plausible. If the event
rate is substantially discordant with the sample size
estimate the investigation team will decide whether an
amendment to the trial protocol is warranted, and ap-
propriate approvals (e.g., from ethical review boards) will
be sought.Recruitment
Patients admitted to study hospitals will only be
approached for potential participation if they meet the
following inclusion criteria: diagnosed with acute coron-
ary syndrome (ACS) and type 2 diabetes. Acute coronary
syndrome is defined as ST-segment elevation myocardial
infarction (STEMI), non-STEMI, or unstable angina
[19]. Participants will be excluded from participation in
the study if they are critically ill, unconscious, on re-
spiratory ventilation, and/or have a current significant
cognitive impairment, determined by the treating spe-
cialist or his/her nominated physician. Patients eligible
for participation will be provided with a participant in-
formation and consent form and will be required to
provide written informed consent prior to their
participation.
Prior to baseline data collection, eligible patients will
be recruited by a research assistant (RA) during their
hospital admission. The RA will be a hospital staff mem-
ber and will obtain individual patient’s informed consent.
Consenting participants will then be assigned a trial par-
ticipant number which will be used during the random-
isation process where they will be allocated to either the
control or intervention group.
Randomisation, concealment and group allocation
A computerised random number sequence generated by
an independent statistician (not involved in the day-to-
day trial) will be used to allocate each participant to the
control or intervention group in a one-to-one ratio.
Group allocation is concealed in opaque envelopes that
stored in a lockable filing cabinet accessible to a ran-
domisation gatekeeper (an administration officer not
otherwise involved in the conduct of the trial). After a
patient has been recruited, the member of the research
team responsible for co-ordinating intervention alloca-
tion will telephone the randomisation gatekeeper to re-
veal the group to which that participant has been
allocated. Group allocation will then only be known by
the randomisation gatekeeper, the person responsible for
the intervention allocation and those providing the inter-
vention (ResN) at each participating site. Participants
will not be directly told their group allocation (in terms
of usual care or intervention). Control group partici-
pants will continue to receive the usual standard care
while participants in the intervention group will receive
usual care as well as the Cardiac-Diabetes Transcare
Program.
Intervention: cardiac-diabetes transcare program
While in hospital
After randomisation the ResN visits the participant in
hospital and delivers 2 education sessions. These ses-
sions focus on:
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and their skill and confidence in their self-management;
2) providing the patient with examples or models of
someone with similar conditions, by showing them
relevant segments or the entirety of the digital video
of the Cardiac -Diabetes Self-Management Program,
“Refocusing Your Life” [12]. The participant will
then be given a copy of the digital video (e.g. a
Digital Video Disc), a new blood glucose meter and
lancing device as well as supplies and blood glucose
recording sheets. Opportunities for questions and
answers will also be provided during these sessions.
After discharge home
The ResN will conduct an in-home visit within the first
week post hospital discharge. The visit will ensure
participants: 1) have sufficient support and required in-
formation; 2) understand individual management goals;
3) are able to carry out self-management activities in the
home environment; 4) understand their treatment regi-
mens; and 5) are provided reinforcement and further
necessary explanations of self-management.
Following the home-visit, the nurse will conduct
weekly telephone follow-ups for 4 weeks, and monthly
up to 6 months. The purpose of the individual telephone
calls is to ensure participants continue to monitor and
manage their conditions, to update their self-
management goals according to individual recovery, as
well as providing encouragement and feedback to the
participant. For patients allocated to the control group,
participants will receive usual standard care including
routine rehabilitation advice and being referred to a local
diabetes educator as the usual treating clinical team
deem necessary.
Data collection
A RA blinded to group allocation will undertake all data
collection. Baseline data will be collected by the RA at
the patients’ earliest convenience (within 48 h of recruit-
ment). Follow-up assessments (1, 3 and 6 months) will
be conducted at a location convenient for the participant
(e.g. at their home) and will be recorded by the RA.
Measures
Outcome measures will include: The primary outcome
for effectiveness is readmission to hospital, as recorded
in patients’ medical record, hospital administrative re-
cords, or patient report of readmission to a non-
participating hospital (e.g. while travelling). Secondary
outcomes include health status (e.g. blood pressure,
blood glucose levels documented on the medical record),
Assessment of Quality of Life (AQoL) [20] for health-
related quality of life, Self-efficacy for Managing Chronic
Disease 6-item Scale [21] for self-management, MedicalOutcomes Study Social Support Survey [22] for psycho-
social well-being, Patient self-report for Health Service
Utilisation Questionnaire [23] as well as Medicare and
Pharmaceutical Benefits Scheme claims information, and
hospital administrative data for healthcare related resource
usage to which healthcare costs will be attributed.
Data analysis
Data analysis will be conducted using intention-to-treat
principles. The following analyses will be undertaken:
1) Baseline data for both the intervention and control
groups will be examined to check for similarity of
the groups. Variables with potential differences
between groups at baseline will be controlled for
during subsequent analyses.
2) Comparisons between groups will be undertaken to
examine the effect of being allocated to the
intervention versus control group on the primary
and secondary outcomes using generalised linear
mixed modelling. These analyses will be adjusted for
age and gender in addition to any variables with
potential between group differences identified at
baseline.
3) Healthcare costs (healthcare system and intervention-
related costs) over the 6-month follow-up will be
summarised for control and intervention group
participants.
4) A trial based economic evaluation will also be
conducted alongside the randomised controlled trial
(RCT) to quantify the additional costs (or cost
savings) per health benefit (Quality Adjusted Life
Years (QALYs)) attributable to the intervention in
comparison to usual care alone. This will be
expressed in the form of an incremental cost
effectiveness ratio. All costs will be measured in
Australian dollars for the year of study completion.
Bootstrap re-sampling of trial data will be used to
construct 95% confidence ellipses and cost-
effectiveness acceptability curves will be prepared.
Sensitivity analyses will be conducted to examine the
robustness of these estimates to change in cost,
effect, time-horizon, and background context data.
Ethical considerations
Ethical approvals and agreements have been obtained
from all study sites and university settings involved in
the study, specifically: Royal Brisbane and Women’s
Hospital (Ref No RBWH HREC/14/QRBW/301), St
Vincent’s Hospital Melbourne (Ref No: HREC-A 127/4),
and Australian Catholic University (Ref No: 2014 309Q)
Human Research Ethics Committees, as well as obtain-
ing an approval by the Department of Human Services
External Request Evaluation Committee (EREC) (Ref No:
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and costs from Medicare and Pharmaceutical Benefits
Scheme (PBS) database. The trial may be audited
according to the practices of the participating facilities at
the discretion of their human research ethics committees
or research governance offices. All ethical considerations
including obtaining individual patient’s informed
consent, emphasising voluntary participation, ensuring
privacy and confidentiality, secure storage of data, and
strict authorised personnel accessibility to the data will
be strictly adhered to.
This study does not have a data monitoring committee
as it is not a trial of a new drug or medical device. The
intervention being trialled is designed to promote adher-
ence to recommended disease management strategies
during the transition from hospital to home. It is not an-
ticipated that there will be any adverse events associated
with participation in the trial; however, all trial personnel
will be encouraged to report any potential adverse events
that may occur during the trial through the usual hos-
pital incident reporting systems, as well as to the trial
investigators for review and reported directly to the
human research ethics committee at the relevant partici-
pating site as well as notifying human research ethics
committees at other sites.
This study protocol (version 1.01) has been prepared in
compliance with the Helsinki Declaration, and has been pro-
spectively registered with the Australia and New Zealand
Clinical Trials Registry (ACTRN12614001317684). If any
amendment to this trial protocol is required, investigator
MC will be responsible for disseminating this information to
trial personnel, and human research ethics committees at
the participating sites. This study protocol has been pre-
pared following the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines. Trial
findings will be reported through peer-reviewed publications
with authorship determined in accordance with the
International Committee of Medical Journal Editors
recommendations.
Discussion
It has been estimated that approximately 25% of
patients with ACS have comorbid type 2 diabetes [24].
These patients have higher morbidity and mortality
rates compared to those without diabetes, and have
higher rehospitalisation rates [25]. Internationally, the
proportion of patients hospitalised with ACS is likely to
increase as a result of ageing populations [26] and the
number of patients being diagnosed with type 2
diabetes is also rising [1–3, 24]. Higher projected inci-
dence and prevalence of these conditions have made
management of these diseases priority areas for
research in many countries due to large potential per-
sonal and economic costs [1–3, 24, 25].Evidence from prior research has indicated cardiac re-
habilitation and diabetes self-management programs
which include strategies for risk factor reduction, in-
creasing physical activity and psychosocial management
are beneficial in the management of these conditions
and can subsequently decrease hospitalisations [27].
However, there is a paucity of literature reporting the
comparative effectiveness of interventions addressing the
needs of patients with dual diagnoses of ACS and type 2
diabetes who are transitioning to home after an acute
hospital admission. Patients with both conditions may
have insufficient adherence to treatment regimens and
lower cardiac rehabilitation completion rates [28, 29]
that may contribute to negative health events and avoid-
able hospital presesmntations.
Our previous randomised controlled trials undertaken
in a general medical population of hospitalised older
adults have demonstrated significant reductions in read-
missions, improved quality of life and cost effectiveness
through implementation of a theory based intervention
comprising home visit and telephone follow up after dis-
charge from hospital [8, 30]. Additionally, our previous
work has addressed a number of gaps in the literature
regarding needs of ACS patients with type 2 diabetes,
and we have piloted cardiac-diabetes self-management
programs in preparation for the present trial. Results
from this preparatory work have demonstrated the feasi-
bility of the program and a favourable effect on patient
self-efficacy [12]. This proposed study builds on previous
work through delivering an intervention prepared with a
multidisciplinary team, to be evaluated in a randomised
controlled trial across two states in Australia to evaluate
the clinical and cost effectiveness of this cardiac-diabetes
TRANSCARE program.
Limitations and strengths
This study faces pragmatic challenges associated with in-
vestigator initiated trials delivering an intervention at
more than one site, alongside administration-related
challenges from multi-institutional collaboration. How-
ever, this may also be considered a strength of the study
as the involvement of more than one study site may en-
hance the ability to generalise findings from the trial.
The investigators have also taken steps to safeguard
consistency in the conduct of the trial between sites by
ensuring one person is responsible for training the re-
search assistants for the trial, as well as the research
nurses delivering the intervention. The same person is
also the main contact point for any concerns that may
arise during the trial regarding patient recruitment or
data collection. Regular monitoring visits will be made
throughout the trial to ensure consistency and integrity
of the intervention is maintained. Another limitation of
the trial pertains to uncertainty that has been described
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restraints associated with the administration of grant
funding, uncertain recruitment rates and no prior effect
size data derived from a sample that is closely matched
to the anticipated trial population. Instead, power calcu-
lations have been estimated for a maximum (target)
sample size and possible smaller sample sizes that may
occur based on the assumption of a more conservative
effect than that observed from a similar intervention ap-
proach among hospitalised older adults (not targeted to
ACS and diabetes).
Conclusion
This study protocol has described a randomised trial
that will evaluate an intervention program for patients
with ACS and Type 2 diabetes commencing in an in-
patient hospital setting and transitioning to the home
environment. The theory-based intervention comprising
face-to-face sessions and telephone follow up aims to in-
crease self-efficacy to enhance self-management behav-
iours and thus improve health outcomes and reduce
hospital readmissions.
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